Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available.
IRLAB Therapeutics AB, a Swedish biotech specializing in innovative Parkinson’s disease therapies, is advancing a diversified pipeline that spans late-stage candidates for levodopa-induced dyskinesias and fall reduction, as well as earlier-stage projects targeting apathy and other neurodegenerative symptoms. The company leverages a proprietary systems biology platform to support its clinical and preclinical programs and strengthen its positioning in neurology-focused drug development.
IRLAB announced it will present at Life Science Day in Gothenburg on March 4, 2026, where CFO Gustaf Albèrt will give an update followed by a Q&A session. Participation in this investor-oriented event, organized to showcase life science companies, provides IRLAB with a platform to highlight its pipeline progress, increase visibility among investors and industry stakeholders, and potentially support future financing and partnership opportunities.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK1.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Sweden-based biopharmaceutical company focused on discovering and developing transformative treatments for all stages of Parkinson’s disease and related neurodegenerative disorders. Originating from Nobel Laureate Arvid Carlsson’s research, it uses its proprietary Integrative Screening Process platform to build a pipeline that includes clinical candidates mesdopetam, pirepemat and IRL757, as well as preclinical programs IRL942 and IRL1117, and is listed on Nasdaq Stockholm.
YTD Price Performance: -12.79%
Average Trading Volume: 241,255
Technical Sentiment Signal: Sell
Current Market Cap: SEK145.9M
See more data about IRLAB.A stock on TipRanks’ Stock Analysis page.